person · Reporting owner

Thakral Anshul

Disclosed activity across 2 companies

Tapewire entity: 25463
SEC CIK: 0001801747

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Fortrea Holdings Inc.FTRE · Entity 4623	Director · Chief Executive Officer	August 06, 2026	August 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Fortrea Holdings Inc.

Report date August 06, 2026 · Filed August 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	204,940	Last balance in matching sequence After 2026-08-06 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-08-06 · Sale · Disposed 55,882 · Balance 260,915 F1: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Such vesting occurred on August 4, 2026 and was reported on a Form 4 filed on August 6, 2026. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2: This transaction was executed in multiple trades at prices ranging from $18.12 to $18.93. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: This number reflects the aggregate amount of Common Stock held by the reporting person. Row 2 · 2026-08-06 · Sale · Disposed 55,975 · Balance 204,940 F1: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Such vesting occurred on August 4, 2026 and was reported on a Form 4 filed on August 6, 2026. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F4: This transaction was executed in multiple trades at prices ranging from $17.86 to $18.12. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: This number reflects the aggregate amount of Common Stock held by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Such vesting occurred on August 4, 2026 and was reported on a Form 4 filed on August 6, 2026. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $18.12 to $18.93. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This number reflects the aggregate amount of Common Stock held by the reporting person.

F4: This transaction was executed in multiple trades at prices ranging from $17.86 to $18.12. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PPD, Inc.

Report date December 08, 2021 · Filed December 08, 2021

Section 16 reporting ended · disclosed 2021-12-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2021-12-08 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2021-12-08 · Disposition to issuer · Disposed 34,226 · Balance 0 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Row 2 · 2021-12-08 · Grant · Acquired 25,522 · Balance 25,522 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. Row 3 · 2021-12-08 · Disposition to issuer · Disposed 25,522 · Balance 0 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.05 · Expires 2027-05-11	Direct	0	Reported balance After 2021-12-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-08 · Disposition to issuer · Disposed 207,836 · Balance 0 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F4: These options, of which 29,904 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 · Expires 2027-05-11	Direct	224,119	Reported balance After 2021-12-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-12-08 · Grant · Acquired 29,907 · Balance 224,119 F5: These options, of which (i) 132,909 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 29,907 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 · Expires 2027-05-11	Direct	0	Reported balance After 2021-12-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-12-08 · Disposition to issuer · Disposed 224,119 · Balance 0 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F5: These options, of which (i) 132,909 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 29,907 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.99 · Expires 2028-12-14	Direct	38,560	Reported balance After 2021-12-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-12-08 · Grant · Acquired 7,711 · Balance 38,560 F6: These options, of which (i) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal tranches for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.99 · Expires 2028-12-14	Direct	0	Reported balance After 2021-12-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-12-08 · Disposition to issuer · Disposed 38,560 · Balance 0 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F6: These options, of which (i) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal tranches for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.70 · Expires 2029-11-26	Direct	69,123	Reported balance After 2021-12-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-12-08 · Grant · Acquired 18,432 · Balance 69,123 F7: These options, of which (i) 13,824 were unvested and scheduled to vest in equal installments on November 26, 2022, 2023, and 2024, (ii) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (iii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal installments for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.70 · Expires 2029-11-26	Direct	0	Reported balance After 2021-12-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-12-08 · Disposition to issuer · Disposed 69,123 · Balance 0 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F7: These options, of which (i) 13,824 were unvested and scheduled to vest in equal installments on November 26, 2022, 2023, and 2024, (ii) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (iii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal installments for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.45 · Expires 2028-12-14	Direct	0	Reported balance After 2021-12-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-12-08 · Disposition to issuer · Disposed 12,853 · Balance 0 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F8: This option, which provided for vesting in five equal installments beginning on December 14, 2019, was canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.22 · Expires 2031-02-11	Direct	0	Reported balance After 2021-12-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-12-08 · Disposition to issuer · Disposed 151,747 · Balance 0 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F9: This option, of which (i) 122,624 provided for vesting on the third anniversary of the grant date and (ii) 29,123 provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

F3: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger.

F4: These options, of which 29,904 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

F5: These options, of which (i) 132,909 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 29,907 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

F6: These options, of which (i) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal tranches for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

F7: These options, of which (i) 13,824 were unvested and scheduled to vest in equal installments on November 26, 2022, 2023, and 2024, (ii) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (iii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal installments for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

F8: This option, which provided for vesting in five equal installments beginning on December 14, 2019, was canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

F9: This option, of which (i) 122,624 provided for vesting on the third anniversary of the grant date and (ii) 29,123 provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 06, 2026 Filed Aug 7, 2026 20:05 UTC	Fortrea Holdings Inc. FTRE · Entity 4623	SaleCommon Stock	55,975	$18.06	$1,010,908.50	Disclosure SEC source: 0001965040-26-000119 · form4.xml · nonDerivative · entry 2 Thakral Anshul · CIK 0001801747 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,940 F1 · security: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Such vesting occurred on August 4, 2026 and was reported on a Form 4 filed on August 6, 2026. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $17.86 to $18.12. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document
August 06, 2026 Filed Aug 7, 2026 20:05 UTC	Fortrea Holdings Inc. FTRE · Entity 4623	SaleCommon Stock	55,882	$18.17	$1,015,375.94	Disclosure SEC source: 0001965040-26-000119 · form4.xml · nonDerivative · entry 1 Thakral Anshul · CIK 0001801747 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,915 F1 · security: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Such vesting occurred on August 4, 2026 and was reported on a Form 4 filed on August 6, 2026. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.12 to $18.93. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document
August 05, 2026 Filed Aug 6, 2026 20:18 UTC	Fortrea Holdings Inc. FTRE · Entity 4623	SaleCommon Stock	50,417	$19.28	$972,039.76	Disclosure SEC source: 0001965040-26-000116 · form4.xml · nonDerivative · entry 3 Thakral Anshul · CIK 0001801747 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,797 F2 · security: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $19.09 to $19.71. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document
August 05, 2026 Filed Aug 6, 2026 20:18 UTC	Fortrea Holdings Inc. FTRE · Entity 4623	SaleCommon Stock	49,452	$19.03	$941,071.56	Disclosure SEC source: 0001965040-26-000116 · form4.xml · nonDerivative · entry 2 Thakral Anshul · CIK 0001801747 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,214 F2 · security: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $18.34 to $19.09. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document
August 04, 2026 Filed Aug 6, 2026 20:18 UTC	Fortrea Holdings Inc. FTRE · Entity 4623	Exercise / conversionRestricted Stock Unit · Derivative	416,666	$0.00	$0.00	Disclosure SEC source: 0001965040-26-000116 · form4.xml · derivative · entry 4 Thakral Anshul · CIK 0001801747 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833,334 Underlying: Common Stock · 416,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F6 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on August 4, 2026. F6 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on August 4, 2026. F7 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document
August 04, 2026 Filed Aug 6, 2026 20:18 UTC	Fortrea Holdings Inc. FTRE · Entity 4623	Exercise / conversionCommon Stock	416,666	$0.00	$0.00	Disclosure SEC source: 0001965040-26-000116 · form4.xml · nonDerivative · entry 1 Thakral Anshul · CIK 0001801747 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. Read SEC document
August 04, 2025 Filed Aug 4, 2025 20:20 UTC	Fortrea Holdings Inc. FTRE · Entity 4623	GrantRestricted Stock Unit · Derivative	1,250,000	$0.00	$0.00	Disclosure SEC source: 0001127602-25-019946 · form4.xml · derivative · entry 1 Thakral Anshul · CIK 0001801747 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents Restricted Stock Units ("RSUs") granted to the Reporting Person on August 4, 2025 under the Fortrea Holdings Inc. 2025 Inducement Award Plan. Each RSU represents the right to receive, at settlement, one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on August 4, 2026. F2 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on August 4, 2026. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerStock Options (Right to Buy) · Derivative	151,747	Not disclosed Strike: $37.22	Not disclosed	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · derivative · entry 12 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 151,747 shares Expires 2031-02-11 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F9 · price: This option, of which (i) 122,624 provided for vesting on the third anniversary of the grant date and (ii) 29,123 provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement. F9 · derivative.exercise_date: This option, of which (i) 122,624 provided for vesting on the third anniversary of the grant date and (ii) 29,123 provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerStock Options (Right to Buy) · Derivative	12,853	Not disclosed Strike: $19.45	Not disclosed	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · derivative · entry 11 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,853 shares Expires 2028-12-14 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F8 · price: This option, which provided for vesting in five equal installments beginning on December 14, 2019, was canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F8 · derivative.exercise_date: This option, which provided for vesting in five equal installments beginning on December 14, 2019, was canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerStock Options (Right to Buy) · Derivative	69,123	$25.80 Strike: $21.70	$1,783,373.40	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · derivative · entry 10 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,123 shares Expires 2029-11-26 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F7 · price: These options, of which (i) 13,824 were unvested and scheduled to vest in equal installments on November 26, 2022, 2023, and 2024, (ii) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (iii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal installments for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F7 · derivative.exercise_date: These options, of which (i) 13,824 were unvested and scheduled to vest in equal installments on November 26, 2022, 2023, and 2024, (ii) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (iii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal installments for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	18,432	$0.00 Strike: $21.70	$0.00	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · derivative · entry 9 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,123 Underlying: Common Stock · 18,432 shares Expires 2029-11-26 F7 · kind: These options, of which (i) 13,824 were unvested and scheduled to vest in equal installments on November 26, 2022, 2023, and 2024, (ii) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (iii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal installments for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F7 · derivative.exercise_date: These options, of which (i) 13,824 were unvested and scheduled to vest in equal installments on November 26, 2022, 2023, and 2024, (ii) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (iii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal installments for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerStock Options (Right to Buy) · Derivative	38,560	$32.51 Strike: $14.99	$1,253,585.60	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · derivative · entry 8 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,560 shares Expires 2028-12-14 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F6 · price: These options, of which (i) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal tranches for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F6 · derivative.exercise_date: These options, of which (i) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal tranches for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	7,711	$0.00 Strike: $14.99	$0.00	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · derivative · entry 7 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,560 Underlying: Common Stock · 7,711 shares Expires 2028-12-14 F6 · kind: These options, of which (i) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal tranches for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F6 · derivative.exercise_date: These options, of which (i) 25,707 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) an aggregate of 7,711 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions in equal tranches for the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerStock Options (Right to Buy) · Derivative	224,119	$36.91 Strike: $10.59	$8,272,232.29	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · derivative · entry 6 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 224,119 shares Expires 2027-05-11 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F5 · price: These options, of which (i) 132,909 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 29,907 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F5 · derivative.exercise_date: These options, of which (i) 132,909 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 29,907 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	29,907	$0.00 Strike: $10.59	$0.00	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · derivative · entry 5 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,119 Underlying: Common Stock · 29,907 shares Expires 2027-05-11 F5 · kind: These options, of which (i) 132,909 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 29,907 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F5 · derivative.exercise_date: These options, of which (i) 132,909 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 29,907 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerStock Options (Right to Buy) · Derivative	207,836	$32.45 Strike: $15.05	$6,744,278.20	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · derivative · entry 4 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 207,836 shares Expires 2027-05-11 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F4 · price: These options, of which 29,904 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F4 · derivative.exercise_date: These options, of which 29,904 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerCommon Stock	25,522	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · nonDerivative · entry 3 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3 · price: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon Stock	25,522	$0.00	$0.00	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · nonDerivative · entry 2 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,522 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3 · kind: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. F3 · shares: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerCommon Stock	34,226	$47.50	$1,625,735.00	Disclosure SEC source: 0001437749-21-028106 · rdgdoc.xml · nonDerivative · entry 1 Thakral Anshul · CIK 0001801747 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · price: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Read SEC document
February 11, 2021 Filed Feb 16, 2021 22:14 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	151,747	$0.00 Strike: $37.22	$0.00	Disclosure SEC source: 0000899243-21-006678 · doc4.xml · derivative · entry 4 Thakral Anshul · CIK 0001801747 · See Remarks. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,747 Underlying: Common Stock · 151,747 shares Expires 2031-02-11 F5 · derivative.exercise_date: These options to purchase common stock vest with 122,624 vesting on the third anniversary of the grant date and 29,123 vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document
February 11, 2021 Filed Feb 16, 2021 22:14 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	4,609	$0.00 Strike: $21.70	$0.00	Disclosure SEC source: 0000899243-21-006678 · doc4.xml · derivative · entry 3 Thakral Anshul · CIK 0001801747 · See Remarks. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,691 Underlying: Common Stock · 4,609 shares Expires 2029-11-26 F1 · kind: Represents previously awarded stock options vesting upon the achievement of certain EBITDA vesting conditions for fiscal 2020, which were determined to be earned subject to the receipt by the Issuer of the completed audit of its fiscal 2020 financial statements. F4 · derivative.exercise_date: Represents 27,650 stock options of which 9,217 are vested and 18,433 of which are unvested and will vest in equal annual installments on November 26, 2021, November 26, 2022, November 26, 2023 and November 26, 2024 and 23,041 stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 18,432 stock options with an exercise price of $21.70 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal years 2021-2024. Read SEC document
February 11, 2021 Filed Feb 16, 2021 22:14 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	2,699	$0.00 Strike: $14.99	$0.00	Disclosure SEC source: 0000899243-21-006678 · doc4.xml · derivative · entry 2 Thakral Anshul · CIK 0001801747 · See Remarks. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,849 Underlying: Common Stock · 2,699 shares Expires 2028-12-14 F1 · kind: Represents previously awarded stock options vesting upon the achievement of certain EBITDA vesting conditions for fiscal 2020, which were determined to be earned subject to the receipt by the Issuer of the completed audit of its fiscal 2020 financial statements. F3 · derivative.exercise_date: Represents 5,142 vested stock options and 25,707 unvested stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 7,711 stock options with an exercise price of $14.99 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal years 2021-2023. Read SEC document
February 11, 2021 Filed Feb 16, 2021 22:14 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	32,894	$0.00 Strike: $10.59	$0.00	Disclosure SEC source: 0000899243-21-006678 · doc4.xml · derivative · entry 1 Thakral Anshul · CIK 0001801747 · See Remarks. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,212 Underlying: Common Stock · 32,894 shares Expires 2027-05-11 F1 · kind: Represents previously awarded stock options vesting upon the achievement of certain EBITDA vesting conditions for fiscal 2020, which were determined to be earned subject to the receipt by the Issuer of the completed audit of its fiscal 2020 financial statements. F2 · derivative.exercise_date: Represents 61,303 vested stock options and 132,909 unvested stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 29,907 stock options with an exercise price of $10.59 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal year 2021. Read SEC document
February 19, 2020 Filed Feb 22, 2020 00:00 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	2,443	$0.00 Strike: $14.99	$0.00	Disclosure SEC source: 0000899243-20-005521 · doc4.xml · derivative · entry 2 Thakral Anshul · CIK 0001801747 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,150 Underlying: Common Stock · 2,443 shares Expires 2028-12-14 F1 · kind: Represents previously awarded stock options earned upon the achievement of certain EBITDA vesting conditions for fiscal 2019. F3 · derivative.exercise_date: Represents 2,443 vested stock options and 25,707 unvested stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 10,410 stock options with an exercise price of $14.99 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal years 2020-2023. Read SEC document
February 19, 2020 Filed Feb 22, 2020 00:00 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	28,409	$0.00 Strike: $10.59	$0.00	Disclosure SEC source: 0000899243-20-005521 · doc4.xml · derivative · entry 1 Thakral Anshul · CIK 0001801747 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,318 Underlying: Common Stock · 28,409 shares Expires 2027-05-11 F1 · kind: Represents previously awarded stock options earned upon the achievement of certain EBITDA vesting conditions for fiscal 2019. F2 · derivative.exercise_date: Represents 28,409 vested stock options and 132,909 unvested stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 62,801 stock options with an exercise price of $10.59 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal years 2020-2021. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:16 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon stock	34,226	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004250 · doc4.xml · nonDerivative · entry 2 Thakral Anshul · CIK 0001801747 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,226 F1 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:16 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerNon-voting common stock	34,226	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004250 · doc4.xml · nonDerivative · entry 1 Thakral Anshul · CIK 0001801747 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. F1 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. Read SEC document
November 26, 2019 Filed Feb 12, 2020 21:16 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	46,082	$0.00 Strike: $21.70	$0.00	Disclosure SEC source: 0000899243-20-004250 · doc4.xml · derivative · entry 3 Thakral Anshul · CIK 0001801747 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,082 Underlying: Non-voting common stock · 46,082 shares Expires 2029-11-26 F2 · kind: Represents stock options previously granted to the reporting person on November 26, 2019. These stock options were already reflected on the reporting person's previously filed Form 3. F3 · derivative.exercise_date: Represents 23,041 stock options which are unvested and will vest in equal annual installments on November 26, 2020, November 26, 2021, November 26, 2022, November 26, 2023 and November 26, 2024 and 23,041 stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 23,041 stock options with an exercise price of $21.70 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal years 2020-2024. F1 · derivative.underlying: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.